Case Report
Successful Management of COVID-19 With Adalimumab in a Post-Coronary Artery Bypass Graft Surgery Patient

https://doi.org/10.1053/j.jvca.2020.12.023Get rights and content

Highlights

  • •

    Adalimumab may be a promising agent for the management of COVID-19.

  • •

    Healing speed of the lungs with adalimumab in COVID-19 is considerable.

  • •

    Adalimumab could be a fast way to control the over-inflammation of COVID-19.

Key Words

adalimumab
Coronary Artery Bypass Graft Surgery
COVID-19

Cited by (0)

The study was supported by Shahid Beheshti University of Medical Sciences.

The study was approved by the Ethics Committee of the National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran, with the ethics code number of IR.SBMU.NRITLD.REC.1399.154.

View Abstract
© 2020 Elsevier Inc. All rights reserved.